We have developed the world's first clinical diagnostic tool designed to detect immune system dysfunction as a leading cause of pregnancy loss.
Our AI-driven platform identifies hidden immune dysfunctions that cause pregnancy loss. By analyzing key biomarkers, we provide doctors with precise insights to personalize treatment and improve birth outcomes—science, not guesswork.
Patient records trained on
Patients validated
Our AI-driven diagnostic tool analyzes a broad range of immune, metabolic, and lifestyle factors to assess the risk of immune-related pregnancy loss. By integrating multiple data points, we provide clinicians with a comprehensive, science-backed assessment to guide personalized treatment.
iFertility evaluates key immune system indicators, identifying imbalances linked to recurrent pregnancy loss. These biomarkers assess immune activation, inflammation, and regulatory function, helping to determine whether an underlying immune dysfunction is impacting pregnancy outcomes.
The system also incorporates metabolic and endocrine markers, which influence immune function and reproductive health. By analyzing these factors, we can detect subtle physiological patterns that may contribute to implantation failure and pregnancy loss.
Beyond laboratory data, lifestyle and patient history play a crucial role in reproductive outcomes. iFertility considers factors such as:
This multi-dimensional approach allows iFertility to detect patterns that traditional methods often miss, providing clinicians with a more precise and actionable diagnosis while maintaining patient safety and privacy.
Recurrent pregnancy loss (RPL) affects 1-5% of women trying to conceive, with many cases remaining unexplained. Our study applies machine learning (ML) to predict pregnancy loss based on pre-pregnancy clinical and immunological factors. Using data from over 36,000 women across five fertility clinics, we trained four ML models—Deep Learning, Random Forest, CatBoost, and SVM—on 22 key biomarkers, including immune cell ratios, autoantibodies, and lifestyle factors. Our models demonstrated exceptional accuracy, with Deep Learning chosen for its ability to handle missing data effectively. This research highlights the potential of AI-driven predictive models in identifying high-risk pregnancies, paving the way for early intervention and personalized treatment strategies. Supported by iFertility Technologies, this study represents a significant step toward AI-driven fertility solutions.
We are developing a novel approach to address certain challenges in early pregnancy by supporting targeted interactions at the maternal-fetal interface. Our method builds upon biological insights to help reduce unfavorable outcomes without relying on conventional, broad-spectrum interventions. This flexible platform is designed with scalability and safety considerations in mind, potentially offering a more precise alternative to conventional options. While preliminary data are promising, we will share further details once our intellectual property protections are fully in place.
We have filed a provisional Australian patent for our AI-driven diagnostic method. This protects our unique approach to analyzing immune and clinical data, securing iFertility’s position as a leader in reproductive immunology AI.
We are launching a cohort validation study, in collaboration with clinics worldwide. This study aims to further validate our findings and refine the clinical applications of our AI-driven diagnostic platform.
We are deeply moved by the impact miscarriage and infertility has on women and their families. The journey to parenthood for some can be difficult and challenging.
The fertility industry is experiencing significant growth, driven by increasing demand for advanced reproductive technologies and services. In 2021, venture capitalists invested $345 million—a 35% increase from 2020—into fertility care startups, reflecting the sector's robust potential.
We are actively seeking investors who share our vision of revolutionizing fertility diagnostics. Your support can accelerate our mission to improve reproductive health outcomes globally. For detailed investment information and to discuss potential collaborations, please contact us directly.
Note: Specific financial figures and projections are available upon request and will be shared confidentially with interested investors.
The team at iFertility have diverse backgrounds, but our journeys have intersected here at iFertility, where we all feel we can have a career making a difference to peoples lives, in a positive way.
Our goal is to build a world class capability that offers families a safe, cost-effective and accessible path to a successful birth.
We truly want to "Create Futures, One Birth at a Time!"
We are actively seeking investors to join us in our journey to make a significant impact to declining birth rates.
Dr. Yousefi brings over 20 years of intensive research in immunology, obstetrics, gynecology, and infertility. He has studied and worked at high-profile universities in Iran, teaching numerous master's and PhD students, and contributing significantly to the field through international seminars, conferences, patents, and over four hundred publications.
Notably, at RC Teb Laboratory, he developed a new method for preparing Autologous Conditioned Serum (ACS), BPT, with significant applications in therapies for osteoarthritis, pregnancy issues, and infertility. His extensive experience provides deep insights into immunology and fertility.
Now, Dr. Yousefi is excited to focus on AI-driven bio data analysis at iFertility, aiming to maximize live birth rates and improve medical services in immunology and infertility.
Vinnie brings over 25 years of technology and implementation experience, with a focus on building cutting-edge AI systems for large organizations, including those in telecommunications, government, and construction.
He holds an Engineering degree with a major in software and a Master's in Project Management. With 8 years of specialized experience in AI development, Vinnie has worked on a variety of successful technology projects.
Vinnie has commited his career and personal funding to join iFertility, as he beleives this initiative is the first time he can contribute to life-changing technology.
